Is Xeris Pharmaceuticals Stock a Good Investment?
Xeris Pharmaceuticals Investment Advice | XERS |
- Examine Xeris Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Xeris Pharmaceuticals' leadership team and their track record. Good management can help Xeris Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Xeris Pharmaceuticals' business and its evolving consumer preferences.
- Compare Xeris Pharmaceuticals' performance and market position to its competitors. Analyze how Xeris Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Xeris Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Xeris Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Xeris Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Xeris Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Xeris Pharmaceuticals Stock
Researching Xeris Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 44.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 0.43. Xeris Pharmaceuticals had not issued any dividends in recent years. The entity had 1:1 split on the 6th of October 2021.
To determine if Xeris Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Xeris Pharmaceuticals' research are outlined below:
| Xeris Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 163.91 M. Net Loss for the year was (62.26 M) with profit before overhead, payroll, taxes, and interest of 152.44 M. | |
| Xeris Pharmaceuticals currently holds about 111.55 M in cash with (47.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.82. | |
| Latest headline from finance.yahoo.com: The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness |
Xeris Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Xeris Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Xeris Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Xeris Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Xeris Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Xeris Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-08 | 2024-09-30 | -0.09 | -0.11 | -0.02 | 22 | ||
2024-05-09 | 2024-03-31 | -0.12 | -0.14 | -0.02 | 16 | ||
2023-11-09 | 2023-09-30 | -0.12 | -0.09 | 0.03 | 25 | ||
2022-08-10 | 2022-06-30 | -0.23 | -0.19 | 0.04 | 17 | ||
2021-05-13 | 2021-03-31 | -0.34 | -0.3 | 0.04 | 11 | ||
2023-05-09 | 2023-03-31 | -0.17 | -0.12 | 0.05 | 29 | ||
2023-03-08 | 2022-12-31 | -0.16 | -0.1 | 0.06 | 37 | ||
2020-08-10 | 2020-06-30 | -0.73 | -0.63 | 0.1 | 13 |
Know Xeris Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Xeris Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Xeris Pharmaceuticals backward and forwards among themselves. Xeris Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Xeris Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.2 M | Walleye Trading Advisors, Llc | 2024-09-30 | 1.1 M | Aqr Capital Management Llc | 2024-09-30 | 1.1 M | Redmile Group, Llc | 2024-09-30 | 1 M | Bank Of America Corp | 2024-09-30 | 1 M | D. E. Shaw & Co Lp | 2024-09-30 | 985 K | Goldman Sachs Group Inc | 2024-09-30 | 836.4 K | Kennedy Capital Management Inc | 2024-09-30 | 604.9 K | Blackrock Inc | 2024-09-30 | 10.7 M | Vanguard Group Inc | 2024-09-30 | 7.8 M |
Xeris Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 490.48 M.Market Cap |
|
Xeris Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.17) | (0.18) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | 8.26 | 8.67 |
Determining Xeris Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Xeris Pharmaceuticals is a good buy. For example, gross profit margin measures Xeris Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Xeris Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Xeris Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Xeris Pharmaceuticals. Check Xeris Pharmaceuticals' Beneish M Score to see the likelihood of Xeris Pharmaceuticals' management manipulating its earnings.
Evaluate Xeris Pharmaceuticals' management efficiency
Xeris Pharmaceuticals has return on total asset (ROA) of (0.087) % which means that it has lost $0.087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.1716) %, meaning that it created substantial loss on money invested by shareholders. Xeris Pharmaceuticals' management efficiency ratios could be used to measure how well Xeris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 8.67 in 2025, whereas Return On Tangible Assets are likely to drop (0.31) in 2025. At this time, Xeris Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 5.5 M in 2025, despite the fact that Net Tangible Assets are likely to grow to (84 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.04) | (0.05) | |
| Tangible Book Value Per Share | (0.91) | (0.96) | |
| Enterprise Value Over EBITDA | (23.51) | (22.34) | |
| Price Book Value Ratio | (54.86) | (52.12) | |
| Enterprise Value Multiple | (23.51) | (22.34) | |
| Price Fair Value | (54.86) | (52.12) | |
| Enterprise Value | 436.8 M | 458.6 M |
The strategic initiatives led by Xeris Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.285 |
Basic technical analysis of Xeris Stock
As of the 23rd of January, Xeris Pharmaceuticals maintains the Market Risk Adjusted Performance of 0.2833, downside deviation of 2.76, and Mean Deviation of 2.15. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xeris Pharmaceuticals, as well as the relationship between them. Please check out Xeris Pharmaceuticals jensen alpha and semi variance to decide if Xeris Pharmaceuticals is priced fairly, providing market reflects its latest price of 3.29 per share. Given that Xeris Pharmaceuticals has jensen alpha of 0.1342, we strongly advise you to confirm Xeris Pharmaceuticals's prevalent market performance to make sure the company can sustain itself at a future point.Xeris Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xeris Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xeris Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Xeris Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Xeris Pharmaceuticals' Outstanding Corporate Bonds
Xeris Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Xeris Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Xeris bonds can be classified according to their maturity, which is the date when Xeris Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| XEROX HLDGS P Corp BondUS98421MAB28 | View | |
| XEROX HLDGS P Corp BondUS98421MAA45 | View | |
| US98420EAB11 Corp BondUS98420EAB11 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Xeris Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Xeris Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0548 | |||
| Market Risk Adjusted Performance | 0.2833 | |||
| Mean Deviation | 2.15 | |||
| Semi Deviation | 2.51 | |||
| Downside Deviation | 2.76 | |||
| Coefficient Of Variation | 1764.53 | |||
| Standard Deviation | 2.79 | |||
| Variance | 7.76 | |||
| Information Ratio | 0.044 | |||
| Jensen Alpha | 0.1342 | |||
| Total Risk Alpha | 0.0643 | |||
| Sortino Ratio | 0.0445 | |||
| Treynor Ratio | 0.2733 | |||
| Maximum Drawdown | 13.86 | |||
| Value At Risk | (4.69) | |||
| Potential Upside | 4.39 | |||
| Downside Variance | 7.59 | |||
| Semi Variance | 6.31 | |||
| Expected Short fall | (2.45) | |||
| Skewness | 0.1958 | |||
| Kurtosis | 0.2534 |
| Risk Adjusted Performance | 0.0548 | |||
| Market Risk Adjusted Performance | 0.2833 | |||
| Mean Deviation | 2.15 | |||
| Semi Deviation | 2.51 | |||
| Downside Deviation | 2.76 | |||
| Coefficient Of Variation | 1764.53 | |||
| Standard Deviation | 2.79 | |||
| Variance | 7.76 | |||
| Information Ratio | 0.044 | |||
| Jensen Alpha | 0.1342 | |||
| Total Risk Alpha | 0.0643 | |||
| Sortino Ratio | 0.0445 | |||
| Treynor Ratio | 0.2733 | |||
| Maximum Drawdown | 13.86 | |||
| Value At Risk | (4.69) | |||
| Potential Upside | 4.39 | |||
| Downside Variance | 7.59 | |||
| Semi Variance | 6.31 | |||
| Expected Short fall | (2.45) | |||
| Skewness | 0.1958 | |||
| Kurtosis | 0.2534 |
Consider Xeris Pharmaceuticals' intraday indicators
Xeris Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Xeris Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 20386.36 | |||
| Daily Balance Of Power | (0.56) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 3.33 | |||
| Day Typical Price | 3.31 | |||
| Price Action Indicator | (0.06) | |||
| Period Momentum Indicator | (0.05) | |||
| Relative Strength Index | 48.99 |
Xeris Pharmaceuticals Corporate Filings
8K | 10th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 7th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 23rd of April 2024 Other Reports | ViewVerify |
Xeris Stock media impact
Far too much social signal, news, headlines, and media speculation about Xeris Pharmaceuticals that are available to investors today. That information is available publicly through Xeris media outlets and privately through word of mouth or via Xeris internal channels. However, regardless of the origin, that massive amount of Xeris data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Xeris Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Xeris Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Xeris Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Xeris Pharmaceuticals alpha.
Xeris Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Xeris Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Xeris Pharmaceuticals Corporate Management
| PharmD D | Senior Affairs | Profile | |
| Beth JD | Chief Secretary | Profile | |
| Steven Pieper | Chief Officer | Profile | |
| Dr MBA | CoFounder Officer | Profile | |
| Paul JD | Senior Advisor | Profile |
Already Invested in Xeris Pharmaceuticals?
The danger of trading Xeris Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Xeris Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Xeris Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Xeris Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.